Barclays Raises Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $25.00

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) had its price objective boosted by stock analysts at Barclays from $22.00 to $25.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has an "overweight" rating on the stock. Barclays's target price would suggest a potential upside of 35.83% from the stock's current price.

Several other equities research analysts have also recently commented on TEVA. Jefferies Financial Group boosted their price objective on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a "buy" rating in a research report on Thursday, June 27th. UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a "buy" rating in a research note on Tuesday, September 3rd. JPMorgan Chase & Co. lifted their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a research note on Monday. StockNews.com upgraded Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 17th. Finally, Argus raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and set a $20.00 price target on the stock in a research report on Wednesday, July 10th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of "Moderate Buy" and an average target price of $19.67.

Teva Pharmaceutical Industries Trading Up 0.1 %

Shares of NYSE TEVA traded up $0.03 during midday trading on Wednesday, reaching $18.41. 4,292,236 shares of the stock were exchanged, compared to its average volume of 9,394,604. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59. Teva Pharmaceutical Industries has a 12 month low of $8.07 and a 12 month high of $19.08. The business has a 50-day simple moving average of $18.01 and a two-hundred day simple moving average of $16.71. The company has a market capitalization of $20.85 billion, a price-to-earnings ratio of -47.20, a P/E/G ratio of 1.29 and a beta of 0.88.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The firm had revenue of $4.16 billion during the quarter, compared to analysts' expectations of $3.99 billion. As a group, equities research analysts expect that Teva Pharmaceutical Industries will post 2.33 EPS for the current year.

Insider Activity at Teva Pharmaceutical Industries

In related news, insider Eric A. Hughes sold 24,537 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the sale, the insider now directly owns 45,060 shares of the company's stock, valued at approximately $777,285. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.55% of the stock is owned by company insiders.

Institutional Trading of Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently bought and sold shares of the business. New Covenant Trust Company N.A. acquired a new position in Teva Pharmaceutical Industries in the first quarter valued at about $28,000. EntryPoint Capital LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at approximately $30,000. UMB Bank n.a. lifted its holdings in shares of Teva Pharmaceutical Industries by 555.6% during the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company's stock worth $44,000 after acquiring an additional 2,067 shares during the period. Beach Investment Counsel Inc. PA acquired a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $48,000. Finally, Byrne Asset Management LLC bought a new stake in Teva Pharmaceutical Industries during the second quarter worth $52,000. Institutional investors and hedge funds own 54.05% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.